Vivacit-E Post-market Follow-up Study

Exclusion Criteria

• •Patient is unwilling or unable to give consent or to comply with the follow-up program.
• •Patient has a total prosthetic hip replacement device (including surface replacement arthroplasty, endoprosthesis, etc. in the affected hip joint(s).
• •Inflammatory Arthritis
• •Rheumatoid Arthritis
• •The patient is:
• •* a prisoner mentally incompetent or unable to understand what participation in the study entails a known alcohol or drug abuser
• •* anticipated to be non-compliant
• •* The patient has an acute, chronic, or systemic infection(s).
• •* The patient has total or partial absence of the muscular or ligamentous apparatus.
• •* The patient has neuromuscular compromise, vascular deficiency or other conditions in the affected limb that may lead to inadequate skeletal fixation.
• •* The patient has osteoradionecrosis.
• •* The patient has lack of bony structures proximal or distal to the operative joint, so that good implant fixation is unlikely or impossible.
• •* The patient has local bone tumors/cysts in the bone to be retained that the implanting surgeon determines could inhibit implant fixation.
• •* The patient is skeletally immature.
• •* The patient has any concomitant disease that can jeopardize the functioning and the success of the implant.
• •* The patient is known to be pregnant.
• •* The patient has a known sensitivity or allergic reaction to one or more of the implanted materials which include metal (titanium, tivanium, tantalum, cobalt, chromium, nickel) and ceramic.